LGL GROUP INC
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
LGL$6.77+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Earnings Per Share
11. Earnings Per Share ("EPS")
The following table presents a reconciliation of Net income (loss) and shares used in calculating basic and diluted net income (loss) per common share for the periods indicated:
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Numerator for EPS: | ||
| Net (loss) income | $(605) | $13 |
| Less: Net income attributable to non-controlling interests | 17 | 19 |
| Net loss attributable to LGL Group common stockholders | $(622) | $(6) |
| Denominator for EPS: | ||
| Weighted average common shares outstanding - basic | 6,410,166 | 5,352,937 |
| Dilutive effects (a): | ||
| Warrants | — | — |
| Stock options | — | — |
| Restricted stock | — | — |
| Weighted average common shares outstanding - diluted | 6,410,166 | 5,352,937 |
| Loss per common share attributable to LGL Group common stockholders: | ||
| Basic | $(0.10) | $(0.00) |
| Diluted | $(0.10) | $(0.00) |
| (a) | For the three months ended March 31, 2026, diluted weighted average common shares outstanding used for calculating earnings per share excludes 50,603 shares issued pursuant to the warrant dividend program completed in January 2026, 49,888 shares issuable upon the exercise of stock options, and 19,523 shares related to restricted stock awards, as the inclusion of these instruments would have been anti-dilutive to the earnings per share calculation. For the three months ended March 31, 2025, diluted weighted average common shares outstanding used for calculating earnings per share excludes warrants to purchase 1,051,664 shares of common stock as well as 36,274 shares related to restricted stock awards, as the inclusion of these instruments would be anti-dilutive to the earnings per share calculation. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.